Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
FDA
Articles
Pfizer to pay record $2.3B penalty over promotions
Pfizer Inc., the world’s largest drug maker, will pay a record $2.3 billion civil and criminal penalty over unlawful prescription
drug promotions, the Justice Department announced today.
POWER BREAKFAST: Panel applauds progress, identifies challenges
A panel of five leaders of the state’s life sciences
industry took on a wide range of topics
July 24 at IBJ’s Power Breakfast
at the Westin Indianapolis.
BREAKING: FDA approves Lilly blood-thinner prasugrel
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Lilly asks FDA to review weekly diabetes drug
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Lilly cancer drug OK’d for new use
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Commercializing science takes too long, Cook says
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Generic meds cost more than consumers realize
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
Lilly expects FDA approval of long-acting version of Zyprexa
Eli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S. Food and Drug Administration on Feb. 6.